RU2004135382A - Замещенные пирролины в качестве ингибиторов киназы - Google Patents
Замещенные пирролины в качестве ингибиторов киназы Download PDFInfo
- Publication number
- RU2004135382A RU2004135382A RU2004135382/04A RU2004135382A RU2004135382A RU 2004135382 A RU2004135382 A RU 2004135382A RU 2004135382/04 A RU2004135382/04 A RU 2004135382/04A RU 2004135382 A RU2004135382 A RU 2004135382A RU 2004135382 A RU2004135382 A RU 2004135382A
- Authority
- RU
- Russia
- Prior art keywords
- alkyl
- group
- aryl
- hydrogen
- compound according
- Prior art date
Links
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 claims 80
- 150000001875 compounds Chemical class 0.000 claims 30
- 229910052739 hydrogen Inorganic materials 0.000 claims 26
- 239000001257 hydrogen Substances 0.000 claims 26
- 229910052736 halogen Inorganic materials 0.000 claims 22
- 150000002367 halogens Chemical class 0.000 claims 22
- 238000000034 method Methods 0.000 claims 20
- 125000001424 substituent group Chemical group 0.000 claims 20
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 16
- 229910052799 carbon Inorganic materials 0.000 claims 14
- 125000004432 carbon atom Chemical group C* 0.000 claims 14
- 125000004093 cyano group Chemical group *C#N 0.000 claims 14
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 13
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 13
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 12
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims 12
- 208000035475 disorder Diseases 0.000 claims 10
- 229910052757 nitrogen Inorganic materials 0.000 claims 8
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 8
- 102000003923 Protein Kinase C Human genes 0.000 claims 7
- 108090000315 Protein Kinase C Proteins 0.000 claims 7
- 108091000080 Phosphotransferase Proteins 0.000 claims 6
- 125000003545 alkoxy group Chemical group 0.000 claims 6
- 125000003118 aryl group Chemical group 0.000 claims 6
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims 6
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims 6
- 102000020233 phosphotransferase Human genes 0.000 claims 6
- KPCZJLGGXRGYIE-UHFFFAOYSA-N [C]1=CC=CN=C1 Chemical group [C]1=CC=CN=C1 KPCZJLGGXRGYIE-UHFFFAOYSA-N 0.000 claims 5
- 125000001072 heteroaryl group Chemical group 0.000 claims 5
- -1 —NR 7 Chemical group 0.000 claims 5
- 108010001483 Glycogen Synthase Proteins 0.000 claims 4
- 101710092490 Protein kinase 3 Proteins 0.000 claims 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims 4
- 206010012601 diabetes mellitus Diseases 0.000 claims 4
- 125000000623 heterocyclic group Chemical group 0.000 claims 4
- 230000001404 mediated effect Effects 0.000 claims 4
- 102000001253 Protein Kinase Human genes 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000026278 immune system disease Diseases 0.000 claims 3
- 125000004043 oxo group Chemical group O=* 0.000 claims 3
- 108060006633 protein kinase Proteins 0.000 claims 3
- 201000004384 Alopecia Diseases 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 206010061876 Obstruction Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 230000003676 hair loss Effects 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- 208000028867 ischemia Diseases 0.000 claims 2
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010059245 Angiopathy Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 208000031229 Cardiomyopathies Diseases 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 208000002705 Glucose Intolerance Diseases 0.000 claims 1
- 206010019196 Head injury Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 102000004877 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- 208000032382 Ischaemic stroke Diseases 0.000 claims 1
- 208000001344 Macular Edema Diseases 0.000 claims 1
- 206010025415 Macular oedema Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010038933 Retinopathy of prematurity Diseases 0.000 claims 1
- 206010038934 Retinopathy proliferative Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 206010064930 age-related macular degeneration Diseases 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000028683 bipolar I disease Diseases 0.000 claims 1
- 230000005907 cancer growth Effects 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 208000015114 central nervous system disease Diseases 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 230000003920 cognitive function Effects 0.000 claims 1
- 230000002526 effect on cardiovascular system Effects 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 208000024963 hair loss Diseases 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 229940125396 insulin Drugs 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 201000010230 macular retinal edema Diseases 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 230000000626 neurodegenerative effect Effects 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 230000000771 oncological effect Effects 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 201000009104 prediabetes syndrome Diseases 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 208000020016 psychiatric disease Diseases 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 210000001957 retinal vein Anatomy 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 125000003831 tetrazolyl group Chemical group 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
- 230000003313 weakening effect Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Virology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38593502P | 2002-06-05 | 2002-06-05 | |
| US60/385,935 | 2002-06-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2004135382A true RU2004135382A (ru) | 2005-06-27 |
Family
ID=29736126
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2004135382/04A RU2004135382A (ru) | 2002-06-05 | 2003-06-04 | Замещенные пирролины в качестве ингибиторов киназы |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US6987110B2 (https=) |
| EP (1) | EP1513830A1 (https=) |
| JP (1) | JP2005531609A (https=) |
| KR (1) | KR20050008787A (https=) |
| CN (1) | CN1671694A (https=) |
| AU (1) | AU2003238874A1 (https=) |
| BR (1) | BR0311821A (https=) |
| CA (1) | CA2488602A1 (https=) |
| CR (1) | CR7606A (https=) |
| IL (1) | IL165515A0 (https=) |
| MX (1) | MXPA04012188A (https=) |
| NO (1) | NO20045699L (https=) |
| RU (1) | RU2004135382A (https=) |
| WO (1) | WO2003104222A1 (https=) |
Families Citing this family (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL156339A0 (en) | 2000-12-08 | 2004-01-04 | Ortho Mcneil Pharm Inc | Indazolyl-substituted pyrroline compounds as kinase inhibitors |
| SE0302546D0 (sv) * | 2003-09-24 | 2003-09-24 | Astrazeneca Ab | New compounds |
| SE0200979D0 (sv) * | 2002-03-28 | 2002-03-28 | Astrazeneca Ab | New compounds |
| ES2300573T3 (es) * | 2002-05-08 | 2008-06-16 | Janssen Pharmaceutica Nv | Inhibidores de cinasa sustituidos con pirrolina. |
| DE60323749D1 (de) * | 2002-06-05 | 2008-11-06 | Janssen Pharmaceutica Nv | Substituierte pyrroline als kinase inhibitoren |
| CA2393720C (en) * | 2002-07-12 | 2010-09-14 | Eli Lilly And Company | Crystalline 2,5-dione-3-(1-methyl-1h-indol-3-yl)-4-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1h-indol-3-yl]-1h-pyrrole mono-hydrochloride |
| AU2002951253A0 (en) * | 2002-09-06 | 2002-09-19 | Medvet Science Pty. Ltd. | A method of modulating cellular activity |
| CA2520590A1 (en) * | 2003-03-27 | 2004-11-04 | Janssen Pharmaceutica, N.V. | Substituted pyrroline kinase inhibitors |
| CA2529353A1 (en) * | 2003-06-13 | 2005-01-06 | Janssen Pharmaceutica N.V. | Substituted indazolyl(indolyl)maleimide derivatives as kinase inhibitors |
| US20080050314A1 (en) * | 2004-02-26 | 2008-02-28 | Bayer Healthcare Ag | Diagnostics and Therapeutics for Diseases Associated With Glycogen Synthase Kinase 3 Beta (Gsk3b) |
| WO2005095983A1 (en) * | 2004-03-04 | 2005-10-13 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with protein kinase c, gamma (prkcg) |
| RU2413511C2 (ru) * | 2004-04-08 | 2011-03-10 | Новартис Аг | Ингибиторы протеинкиназы с, предназначенные для лечения аутоиммунных заболеваний и отторжения трансплантата |
| JP2007532506A (ja) * | 2004-04-08 | 2007-11-15 | ノバルティス アクチエンゲゼルシャフト | 自己免疫疾患および拒絶反応の処置のためのタンパク質キナーゼｃ阻害剤 |
| US20060079568A1 (en) * | 2004-05-21 | 2006-04-13 | The Texas A&M University System | Inhibition of atherosclerosis by diindolylmethane analogs |
| EP1662259A1 (en) * | 2004-11-25 | 2006-05-31 | Cellzome Ag | Use of Eph receptor inhibitors for the treatment of neurodegenerative diseases |
| US8017395B2 (en) | 2004-12-17 | 2011-09-13 | Lifescan, Inc. | Seeding cells on porous supports |
| CA2613889A1 (en) * | 2005-06-08 | 2006-12-14 | Centocor, Inc. | A cellular therapy for ocular degeneration |
| AU2006268908A1 (en) | 2005-07-11 | 2007-01-18 | Novartis Ag | Indolylmaleimide derivatives |
| EP1928437A2 (en) | 2005-08-26 | 2008-06-11 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
| EP2258358A3 (en) | 2005-08-26 | 2011-09-07 | Braincells, Inc. | Neurogenesis with acetylcholinesterase inhibitor |
| US20070088019A1 (en) * | 2005-09-29 | 2007-04-19 | Han-Cheng Zhang | Macroheterocyclic compounds as kinase inhibitors |
| EP1940389A2 (en) | 2005-10-21 | 2008-07-09 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
| US20070112017A1 (en) | 2005-10-31 | 2007-05-17 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| US20090324610A1 (en) * | 2006-04-25 | 2009-12-31 | Kyushu Univeristy, National University Corporation | Gene associated with arteriosclerotic disease, and use thereof |
| US8741643B2 (en) | 2006-04-28 | 2014-06-03 | Lifescan, Inc. | Differentiation of pluripotent stem cells to definitive endoderm lineage |
| AU2007249399A1 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
| JP2008063278A (ja) * | 2006-09-07 | 2008-03-21 | Fujifilm Finechemicals Co Ltd | １−ピリジン−４−イル−インドール類の製造方法 |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| US9080145B2 (en) | 2007-07-01 | 2015-07-14 | Lifescan Corporation | Single pluripotent stem cell culture |
| CA3114827C (en) | 2007-07-31 | 2023-09-05 | Lifescan, Inc. | Differentiation of human embryonic stem cells to pancreatic endocrine |
| EP2229434B1 (en) | 2007-11-27 | 2011-09-07 | Lifescan, Inc. | Differentiation of human embryonic stem cells |
| FR2927075A1 (fr) * | 2008-02-04 | 2009-08-07 | Centre Nat Rech Scient | Molecules comprenant un squelette bis-(heteroaryl)maleimide, et leur utilisation dans l'inhibition d'enzymes |
| KR101731474B1 (ko) | 2008-02-21 | 2017-05-11 | 얀센 바이오테크 인코포레이티드 | 세포 부착, 배양 및 탈리를 위한 방법, 표면 개질 플레이트 및 조성물 |
| US8623648B2 (en) * | 2008-04-24 | 2014-01-07 | Janssen Biotech, Inc. | Treatment of pluripotent cells |
| US20090291982A1 (en) * | 2008-05-22 | 2009-11-26 | Astrazeneca Ab | New Substituted Oxindole Derivative 352 |
| EP2318516A1 (en) * | 2008-06-30 | 2011-05-11 | Centocor Ortho Biotech Inc. | Differentiation of pluripotent stem cells |
| PL2310492T3 (pl) | 2008-06-30 | 2015-12-31 | Janssen Biotech Inc | Różnocowanie pluripotencjalnych komórek macierzystych |
| US20100028307A1 (en) * | 2008-07-31 | 2010-02-04 | O'neil John J | Pluripotent stem cell differentiation |
| MX349178B (es) * | 2008-10-31 | 2017-07-17 | Centocor Ortho Biotech Inc | Diferenciación de células madre embrionarias humanas al linaje endocrino pancreático. |
| PL2346988T3 (pl) * | 2008-10-31 | 2017-10-31 | Janssen Biotech Inc | Różnicowanie ludzkich zarodkowych komórek macierzystych do linii endokrynnej trzustki |
| ES2584053T3 (es) * | 2008-11-20 | 2016-09-23 | Janssen Biotech, Inc. | Métodos y composiciones para la unión de células y cultivo en sustratos planos |
| ES2642070T3 (es) | 2008-11-20 | 2017-11-15 | Janssen Biotech, Inc. | Cultivo de células madre pluripotentes en microportadores |
| WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| EP2456859A4 (en) | 2009-07-20 | 2015-03-18 | Janssen Biotech Inc | DIFFERENTIATION OF HUMAN EMBRYONIC STEM CELLS |
| KR102058901B1 (ko) | 2009-07-20 | 2019-12-24 | 얀센 바이오테크 인코포레이티드 | 인간 배아 줄기 세포의 분화 |
| SG177483A1 (en) | 2009-07-20 | 2012-02-28 | Janssen Biotech Inc | Differentiation of human embryonic stem cells |
| ES2665006T3 (es) * | 2009-10-29 | 2018-04-24 | Janssen Biotech, Inc. | Células madre pluripotentes |
| CA2784425A1 (en) * | 2009-12-23 | 2011-06-30 | Centocor Ortho Biotech Inc. | Differentiation of human embryonic stem cells |
| SG181687A1 (en) | 2009-12-23 | 2012-07-30 | Centocor Ortho Biotech Inc | Differentiation of human embryonic stem cells |
| EP2542667A4 (en) | 2010-03-01 | 2013-07-31 | Janssen Biotech Inc | PROCESS FOR CLEANING CELLS OBTAINED FROM PLURIPOTENTIAL STEM CELLS |
| RU2663339C1 (ru) | 2010-05-12 | 2018-08-03 | Янссен Байотек, Инк. | Дифференцирование эмбриональных стволовых клеток человека |
| CN103221536B (zh) | 2010-08-31 | 2016-08-31 | 詹森生物科技公司 | 人胚胎干细胞的分化 |
| ES2658146T3 (es) | 2010-08-31 | 2018-03-08 | Janssen Biotech, Inc. | Diferenciación de células madre embrionarias humanas |
| EP2611907B1 (en) | 2010-08-31 | 2016-05-04 | Janssen Biotech, Inc. | Differentiation of pluripotent stem cells |
| ES2387359B1 (es) * | 2011-02-25 | 2013-08-01 | Consejo Superior De Investigaciones Científicas (Csic) | Inhibidores de GSK-3 útiles en enfermedades neurodegenerativas, inflamatorias, cáncer, diabetes y en procesos regenerativos |
| KR102203056B1 (ko) | 2011-12-22 | 2021-01-14 | 얀센 바이오테크 인코포레이티드 | 인간 배아 줄기 세포의 단일 인슐린 호르몬 양성 세포로의 분화 |
| HK1206058A1 (en) | 2012-03-07 | 2015-12-31 | Janssen Biotech, Inc. | Defined media for expansion and maintenance of pluripotent stem cells |
| AU2013271581B2 (en) | 2012-06-08 | 2018-08-09 | Janssen Biotech, Inc. | Differentiation of human embryonic stem cells into pancreatic endocrine cells |
| JP6557147B2 (ja) | 2012-12-31 | 2019-08-07 | ヤンセン バイオテツク，インコーポレーテツド | Ｈｂ９調節物を用いたヒト胚性幹細胞の膵臓内分泌細胞への分化 |
| BR112015015770A2 (pt) | 2012-12-31 | 2017-07-11 | Janssen Biotech Inc | cultivo de células-tronco embrionárias humanas na interface ar-líquido para diferenciação em células pancreáticas endócrinas |
| RU2687379C2 (ru) | 2012-12-31 | 2019-05-13 | Янссен Байотек, Инк. | Суспендирование и кластеризация плюрипотентных клеток человека с целью их дифференцировки в панкреатические эндокринные клетки |
| US10370644B2 (en) | 2012-12-31 | 2019-08-06 | Janssen Biotech, Inc. | Method for making human pluripotent suspension cultures and cells derived therefrom |
| US10006006B2 (en) | 2014-05-16 | 2018-06-26 | Janssen Biotech, Inc. | Use of small molecules to enhance MAFA expression in pancreatic endocrine cells |
| DK3443073T3 (da) | 2016-04-14 | 2024-09-02 | Janssen Biotech Inc | Differentiering af pluripotente stamceller til intestinale mellemtarmendodermceller |
| CN109535158B (zh) * | 2016-04-26 | 2021-04-23 | 浙江工业大学 | 一种双芳基马来酰亚胺类化合物及其药学上可接受的盐及其制备方法和应用 |
| EP3920885A1 (en) | 2019-02-08 | 2021-12-15 | Frequency Therapeutics, Inc. | Valproic acid compounds and wnt agonists for treating ear disorders |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ280738B6 (cs) | 1988-02-10 | 1996-04-17 | F. Hoffmann - La Roche And Co., Aktiengesellschaft | Substituované pyrroly, jejich použití pro výrobu léčiv a léčiva na jejich bázi |
| GB8904161D0 (en) | 1989-02-23 | 1989-04-05 | Hoffmann La Roche | Substituted pyrroles |
| US5624949A (en) | 1993-12-07 | 1997-04-29 | Eli Lilly And Company | Protein kinase C inhibitors |
| ES2236702T3 (es) | 1993-12-23 | 2005-07-16 | Eli Lilly And Company | Inhibidores de la proteina quinasa c. |
| EP0888339A4 (en) | 1996-03-20 | 2001-02-28 | Lilly Co Eli | SYNTHESIS OF INDOLYLMALEINIMIDES |
| SE9603283D0 (sv) * | 1996-09-10 | 1996-09-10 | Astra Ab | New compounds |
| AU2548699A (en) * | 1998-02-23 | 1999-09-06 | Rei Asakai | Cell death inhibitors |
| CA2338866A1 (en) | 1998-07-30 | 2000-02-10 | Japan Tobacco Inc. | Disubstituted maleimide compound and pharmaceutical use thereof |
| ATE284387T1 (de) | 1998-10-08 | 2004-12-15 | Smithkline Beecham Plc | 3-(3-chloro-4-hydroxyphenylamino)-4-(2- nitrophenyl)-1h-pyrrol-2,5-dion als glykogen synthase kinase-3 inhibitor (gsk-3) |
| YU4403A (sh) | 2000-07-27 | 2006-05-25 | F. Hoffmann-La Roche Ag. | Derivati 3-indolil-4-fenil-1h-pirol-2,5-diona, kao inhibitori glikogen sintaza kinaze-3 beta |
| AU2002221810B2 (en) | 2000-11-07 | 2005-06-23 | Novartis Ag | Indolylmaleimide derivatives as protein kinase C inhibitors |
-
2003
- 2003-06-04 MX MXPA04012188A patent/MXPA04012188A/es unknown
- 2003-06-04 EP EP03734389A patent/EP1513830A1/en not_active Withdrawn
- 2003-06-04 RU RU2004135382/04A patent/RU2004135382A/ru not_active Application Discontinuation
- 2003-06-04 CA CA002488602A patent/CA2488602A1/en not_active Abandoned
- 2003-06-04 JP JP2004511292A patent/JP2005531609A/ja not_active Withdrawn
- 2003-06-04 CN CNA038184788A patent/CN1671694A/zh active Pending
- 2003-06-04 US US10/454,069 patent/US6987110B2/en not_active Expired - Fee Related
- 2003-06-04 WO PCT/US2003/017569 patent/WO2003104222A1/en not_active Ceased
- 2003-06-04 KR KR10-2004-7019678A patent/KR20050008787A/ko not_active Withdrawn
- 2003-06-04 AU AU2003238874A patent/AU2003238874A1/en not_active Abandoned
- 2003-06-04 BR BR0311821-5A patent/BR0311821A/pt not_active IP Right Cessation
-
2004
- 2004-12-02 IL IL16551504A patent/IL165515A0/xx unknown
- 2004-12-06 CR CR7606A patent/CR7606A/es unknown
- 2004-12-29 NO NO20045699A patent/NO20045699L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA04012188A (es) | 2005-07-25 |
| BR0311821A (pt) | 2005-04-05 |
| CN1671694A (zh) | 2005-09-21 |
| US20040059113A1 (en) | 2004-03-25 |
| CA2488602A1 (en) | 2003-12-18 |
| AU2003238874A1 (en) | 2003-12-22 |
| NO20045699L (no) | 2005-01-28 |
| US6987110B2 (en) | 2006-01-17 |
| WO2003104222A1 (en) | 2003-12-18 |
| IL165515A0 (en) | 2006-01-15 |
| EP1513830A1 (en) | 2005-03-16 |
| JP2005531609A (ja) | 2005-10-20 |
| CR7606A (es) | 2009-01-16 |
| KR20050008787A (ko) | 2005-01-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2004135382A (ru) | Замещенные пирролины в качестве ингибиторов киназы | |
| JP2005531609A5 (https=) | ||
| RU2003120442A (ru) | Макрогетероциклические соединения, полезные в качестве ингибиторов киназы | |
| KR102003030B1 (ko) | 특정 아미노-피리미딘류, 그의 조성물 및 그들의 이용방법 | |
| DE69826841T2 (de) | Phthalazines mit angiogenesis-hemmender wirkung | |
| CN110036005B (zh) | 酰胺衍生物及其在药物中的应用 | |
| EP1869037B1 (en) | Heterobicylic inhibitors of hvc | |
| JP7688681B2 (ja) | アルドース還元酵素阻害剤およびその使用方法 | |
| JP6603213B2 (ja) | 心臓状態に対するピリミジンジオン化合物 | |
| US11851409B2 (en) | Deuterated benzylaminopyrimidinedione derivatives and use thereof | |
| WO2019034096A1 (en) | FUSED BICYCLIC COMPOUNDS AND THEIR USES IN MEDICINE | |
| HK1200361A1 (en) | Substituted aminothiazoles as inhibitors of cancers, including hepatocellular carcinoma, and as inhibitors of hepatitis virus replication | |
| KR20070102693A (ko) | 피리도(3,2-ｄ)피리미딘 및 의학 치료에 유용한 이것의약학적 조성물 | |
| CN111315744B (zh) | 杂芳基并四氢吡啶类化合物、其制备方法、药物组合物及应用 | |
| WO2021027567A1 (zh) | Ep4受体拮抗剂和pd-1抑制剂联合用于癌症的治疗 | |
| CN109745325B (zh) | Fgfr4抑制剂、其制备方法和用途 | |
| CN110938059A (zh) | 胺基脲敏感性胺氧化酶抑制剂制备及其应用 | |
| JP2021525274A (ja) | ピリミジンシクロヘキセニル糖質コルチコイドレセプター調節因子 | |
| CA3243254A1 (en) | HETEROCYCLIC CYCLICAL COMPOUND FUSIONED WITH AN AROMATIC RING USED AS A POTASSIUM CHANNEL REGULATOR, ITS PREPARATION AND USE | |
| EP4619402A1 (en) | Gpr17 modulators and uses thereof | |
| KR102566237B1 (ko) | 사이클로올레핀 치환된 헤테로방향족 화합물 및 그의 용도 | |
| CN105367582A (zh) | 银杏内酯b衍生物及其在药物中的应用 | |
| CN113278013B (zh) | 2,6-二取代的1,2,4-三嗪-3,5-二酮化合物及其制备方法和应用 | |
| TWI879781B (zh) | 吡喃葡萄糖基衍生物及其用途 | |
| CN114478561B (zh) | 一种依帕司他石蒜碱偶联物及其制备方法和用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20070709 |